Date: 2011-02-15
Type of information: Licensing agreement
Compound: Pfenex Expression Technology ™ platform
Company: Boehringer Ingelheim (Germany) Pfenex (USA)
Therapeutic area:
Type agreement: licensing
Action mechanism:
Disease:
Details: Pfenex Inc. and Boehringer Ingelheim International GmbH, have entered into a strategic agreement. It provides Boehringer Ingelheim with non-exclusive access to the Pfenex Expression Technology ™ platform (protein expression platform based on Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals). Under the terms of the multi-year agreement, Pfenex Inc. will engineer production strains and processes for Boehringer Ingelheim’s proprietary molecules, and molecules from Boehringer Ingelheim’s contract manufacturing customers. This collaboration provides Boehringer Ingelheim and their customers with access to an industry-leading expression platform to enable preclinical and clinical development to progress much more quickly and efficiently.
Financial terms: Financial details of the agreement were not disclosed.
Latest news:
